Neurizon has opened a non-underwritten A$2 million share purchase plan at A$0.068 a share, giving eligible shareholders access to the same terms as its recent placement. Participants may also receive one free option for each new share, subject to shareholder approval and ASX quotation conditions, as the company funds its NUZ-001 ALS program towards a late Q2 2027 readout.
- A$2 million non-underwritten SPP at A$0.068 per share
- Eligible Australian and New Zealand shareholders can apply for up to A$30,000
- One potential free option for each SPP share, exercisable at A$0.12
- Funds earmarked for the HEALEY ALS trial and NUZ-001 preparation
- SPP closes on 4 December, with shareholder approval due on 17 December
Neurizon opens shareholder access to A$6.3 million funding plan
Neurizon Therapeutics Limited (ASX:NUZ) has opened the retail-investor leg of its capital raising, targeting a further A$2 million from eligible shareholders at A$0.068 per share. The offer follows a A$4.3 million placement announced earlier this month, putting the combined target at A$6.3 million before costs if the SPP is fully subscribed.
The price gives existing holders access to the same terms as placement participants. It represented a 20.9% discount to Neurizon’s 28 October closing price and an 18.9% discount to the relevant five-day VWAP, while standing 19.3% above the A$0.057 closing price recorded on 12 November. At the SPP target, the company would issue roughly 29.4 million new shares before any scale-back or increase in the offer size.
Free option entitlement depends on the December vote
The more unusual feature is the attached option offer. Participants may be offered one new option for every SPP share subscribed for, at no additional cost, with an exercise price of A$0.12 and an expiry 18 months after issue. The entitlement is not guaranteed: shareholders must approve the option issue at the general meeting expected on 17 December, and ASX quotation conditions must also be satisfied.
The structure extends the financing approach outlined in Neurizon’s A$4.3 million placement, which was announced alongside the company’s plan to seek another A$2 million from shareholders. The SPP itself is non-renounceable and non-underwritten, meaning participation levels will determine how much additional equity Neurizon ultimately raises. The company may increase the target if demand exceeds A$2 million, but it also retains broad discretion to scale back applications.
Funding directed towards NUZ-001 trial and commercial preparation
Neurizon says the funds, combined with existing cash after the redemption of all outstanding convertible notes held by Obsidian Global GP and anticipated research and development tax refunds, will support clinical and pre-clinical work. The priority includes completion of Regimen I of the Phase 2/3 HEALEY ALS Platform Trial, with topline results anticipated in late Q2 2027.
The company also plans to fund manufacturing and supply-chain readiness, regulatory work, business development and corporate costs around NUZ-001. The trial is fully recruited, and the first participant has already completed the randomised phase and entered an optional extension in the fully recruited HEALEY ALS trial. That milestone does not resolve the clinical risk, but it places the financing squarely against a defined upcoming data event.
SPP participation and key approval risks
Eligible shareholders were required to hold shares at 7.00pm on 30 October 2026 and have a registered address in Australia or New Zealand, subject to the offer’s other eligibility rules. Applications range from A$1,000 to A$30,000, and the new shares will rank equally with existing ordinary shares. The SPP closes at 5.00pm Melbourne time on 4 December, with the results and share issue scheduled for 11 December.
For investors, the immediate question is not simply whether the SPP reaches its target, but how much funding Neurizon secures without further reliance on its financing arrangements. The next hard signals are the subscription result, the scale-back decision if demand is strong, and the 17 December shareholder vote that determines whether the proposed option sweetener becomes an issued security rather than just an entitlement on paper.
Bottom Line?
The SPP provides a clear funding bridge towards the late Q2 2027 ALS readout, but its value to shareholders depends on participation, dilution, and approval of the proposed options.
Questions in the middle?
- Will the non-underwritten SPP raise the full A$2 million, or will Neurizon need to adjust the target or rely on other funding sources?
- How much dilution will existing shareholders face once the placement, SPP and potential options are included?
- Will shareholders approve the option issue and will ASX quotation conditions be satisfied before the trial readout?